NEW YORK (GenomeWeb News) – Cenix BioScience today said German drug maker Merck will use its RNAi screening services in its target-discovery and -validation efforts in oncology, with an option to expand in several human disease programs.
 
Terms of the deal call for Cenix to perform high-throughput screens of cultured human cells to discover and validate new therapeutic targets, using assays co-designed with Merck scientists.
 
Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.